Pharma Deal News Today : Breaking News, Live Updates & Top Stories | Vimarsana

for the -- last month. john so it has been a fierce advocate on this issue, and you will not want to miss what he has to say. that is coming up. but first, i want to start tonight with this really weird moment that happened last week at a house hearing. transportation secretary pete pitt a judge was testifying before the house committee, and as you would expect, for several hours, they discussed infrastructure. roads, railways, electric vehicles, energy prices, all the usual stuff. until one republican congressman on the committees suddenly took the transportation hearing off the rai...

transportation secretary pete buttigieg was testifying before the house committee, and as you would expect, for several hours, they discussed infrastructure. roads, railways, electric vehicles, energy prices, all the usual stuff. until one republican congressman on the committee suddenly took the transportation hearing off the rails. and that joke was for you, transport nerds. you're welcome. have a watch. >> we now have president biden in office for 18 months, and just recently, we now see the mainstream media questioning president biden's mental state and for good reason. sadly, he...

tonight with this really weird moment that happened last week at a house hearing. transportation secretary pete buttigieg was testifying before a house committee and as you woulde expect, for several hou, theyfo discussed infrastructure roads, railway, electric vehicles, energy prices, all of the usual stuff until one republican congressman on the committee suddenly took the transportation hearing off the rails. and that joke was for you, transport nerd, you're welcome. have a watch. >> now have president biden in office for 18 months and just recentlyfi we see the mainstrea media qu...

The cash deal, which adds several experimental therapies to AstraZeneca's portfolio, values Gracell at $2 per ordinary share, or $10 per ADS of Gracell, plus a non-tradable contingent value right of $0.30 per ordinary share, if certain regulatory milestones are met.

India could soon see its largest-ever pharma deal as the 10th biggest pharma company by revenues -- Torrent -- is trying to buy the fourth largest one -- Cipla. But, is the bullet too big to bite for Torrent? Is the funding feasible? Will the compatibility not of portfolio but of philosophy, and people, be a challenge? Will Torrent’s M&A ambition extend beyond pharma and power to possibly once again finance? Host Anupriya Nair solves this complex bond along with Economic Times’ Arijit Barman, Kiran Somvanshi & Sangita Mehta in this episode of The Morning Brief podcast. Tune in! Cre...